

**EUROPEAN  
CURRICULUM VITAE  
FORMAT**



**PERSONAL  
INFORMATION**

Name	<b>CONTE PIERFRANCO</b>
Address	Veneto Institute of Oncology IRCCS Division of Medical Oncology 2 University of Padova Via Gattamelata 64 35128 Padova (Italy)
Telephone	+ 39-0498215931
Fax	+ 39-0498215932
E-mail	<a href="mailto:pierfranco.conte@unipd.it">pierfranco.conte@unipd.it</a> ; <a href="mailto:pierfranco.conte@iov.veneto.it">pierfranco.conte@iov.veneto.it</a>
Nationality	Italian
Date of birth	October 5, 1950

**WORK EXPERIENCE**

- Dates (from – to) 02/2014 – present
- Name and address of the employer **Veneto Oncology Network (ROV)**  
**Veneto Region**  
**Veneto Institute of Oncology, IRCCS**  
**Padova (Italy) – website: <http://rov.regione.veneto.it>**
- Occupation or position held **Scientific Coordinator**
- Dates (from – to) 06/2014 – present
- Name and address of the employer Breast Unit (HUB Center)  
Veneto Institute of Oncology ,IRCCS  
Padova (Italy)
- Occupation or position held Chairman
- Dates (from – to) 02/2013 – present
- Name and address of the employer Division of Medical Oncology 2,  
Veneto Institute of Oncology, IRCCS  
Padova (Italy)
- Occupation or position held Chief

- Dates (from – to) 11/2002 – 01/2013
- Name and address of the employer Division of Medical Oncology,  
University Hospital,  
Modena (Italy)
- Occupation or position held Chief
  
- Dates (from – to) 1990-2002
- Name and address of the employer Division of Medical Oncology,  
Saint Chiara Hospital Pisa (Italy)
- Occupation or position held Director
  
- Dates (from – to) 1985-90
- Name and address of the employer Division of Medical Oncology,  
National Institute for Cancer Research,  
Genova (Italy)
- Occupation or position held Deputy Head,
  
- Dates (from – to) 1980-85
- Name and address of the employer Division of Medical Oncology,  
National Institute for Cancer Research,  
Genova (Italy)
- Occupation or position held Assistant Professor
  
- Dates (from – to) 1978-80
- Name and address of the employer Institute of Oncology,  
Torino S. Giovanni Hospital (Italy)
- Occupation or position held Assistant Professor Division of Medical Oncology
  
- Dates (from – to) 1976-78
- Name and address of the employer University of Torino  
School of Medicine
- Occupation or position held Postdoctoral fellowship in Hematology
  
- Dates (from – to) 1975-76
- Name and address of the employer Universite' Libre de Bruxelles  
Dept. of Molecular biology
- Occupation or position held Postdoctoral fellowship

## RESEARCH EXPERIENCE

- Dates (from-to) 2016-Present
- Name and type of organisation University of Padua
  - Main Activities A-BRAVE Trial PHASE III RANDOMIZED TRIAL OF AN ANTI-PD-L1 ANTIBODY AS ADJUVANT OR POST-NEOADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS
  
- Dates (from-to) 2013-Present
- Name and type of organisation University of Padua
  - Main Activities MAINTenance Afinitor (MAIN-A): A randomized trial comparing maintenance Aromatase Inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients with HR + metastatic breast cancer with disease control after first line chemotherapy
  
- Dates (from-to) 2013-Present
- Name and type of organisation Veneto Government

- Main Activities Impact of the Oncotype DX® Breast Cancer Assay on Resources Optimization and Treatment Decisions for Women with Estrogen Receptor- Positive, Node-Negative and Node-Positive Breast Carcinoma: a prospective Italian multicenter study
  
- Dates (from-to) 2013-Present
  - Name and type of organisation University of Padua
  - Main Activities PIK3CA pathway activation and tumor infiltrating lymphocytes (TIL) to predict outcome of HER+ early breast cancer (EBC) patients treated with trastuzumab based therapy in the prospective randomized phase III Short-Her trial.
  
- Dates (from-to) 2009-2012
  - Name and type of organisation Ministry of Health
  - Main Activities Treatment optimization of HER2 positive breast cancer (PI)
  
- Dates (from-to) 2002-2011
  - Name and type of organisation Industry sponsored trials
  - Main Activities PI of 129 trials in solid tumours ( 56 breast, 11 gastro-enteric, 31 genitourinary, 24 lung, 5 melanoma, 2 CNS)
  
- Dates (from-to) 2008-2011
  - Name and type of organisation AIFA
  - Main Activities PI of the ShortHer Trial: national trial sponsored by the Italian Drug Agency (AIFA) to compare 9 weeks vs 1 year of adjuvant trastuzumab in HER2+ early breast cancer
  
- Dates (from-to) 2007-2009
  - Name and type of organisation Emilia Romagna Regional Government
  - Main Activities Identification and clinical validation of predictive and prognostic factors with special focus on molecularly targeted agents (PI)
  
- Dates (from-to) 2006-2008
  - Name and type of organisation Ministry of Health
  - Main Activities Validation of new biomarkers: role in prognosis and therapy guidance (PI)
  
- Dates (from-to) 2003-2007
  - Name and type of organisation
    - AIRC
    - Ministry of Research and Education
  - Main Activities Tumour molecular subtypes and Primary Systemic Treatment with targeted agents in Operable Breast Cancer (PI)
  
- Dates (from-to) 2001-2003
  - Name and type of organisation CNR
  - Main Activities Development of Chemotherapy regimens based on the tumor molecular profile (PI)
  
- Dates (from - to) 1998-2000
  - Name and type of organisation AIRC
  - Main Activities Clinical studies to improve treatment outcomes in metastatic breast cancer patients (PI)
  
- Dates (from-to) 1998
  - Name and type of organisation CNR
  - Main Activities Evaluation of Positron Emission Tomography in breast cancer (PI)
  
- Dates (from-to) 1991-96
  - Name and type of organisation Special project Clinical application of oncologic research, ACRO, CNR
  - Main Activities Accelerated vs conventional chemotherapy in locally advanced breast cancer (PI)
  
- Dates (from-to) 1989-92
  - Name and type of organisation AIRC

- Main Activities                      Biologic modifiers: in vitro and in vivo effects on cancer cells (PI)
- Dates (from-to)                    1987-89
- Name and type of organisation    AIRC
  - Main Activities                    Cytokinetic chemotherapy in breast cancer (PI)
- Dates (from - to)                  1984-89
- Name and type of organisation    Special Project Oncology, PFO, CNR
  - Main Activities                    Determination of growth fraction as a prognostic indicator and to design clinical trials in ovarian and breast cancer (PI)
- Dates (from - to)                  1982-83
- Name and type of organisation    Special Project Oncology, PFO, CNR
  - Main Activities                    Determination of growth fraction as a prognostic indicator and to design clinical trials in ovarian and breast cancer (PI)
- Dates (from-to)                    1982-83
- Name and type of organisation    Committee for technological research, CNR
  - Main Activities                    Development of autoradiographic technique to study the growth fraction of human tumors in vitro (PI)

## **ACCADEMIC POSITION**

- Dates (from - to)                  02/2013- present
- Name and type of organisation    University of Padova
- Principal subjects/occupational skills covered                    Clinical Oncology
- Title of qualification awarded    Full Professor
- Dates (from - to)                  11/2002-02/2013
- Name and type of organisation    Modena School of Medicine
- Principal subjects/occupational skills covered                    Clinical Oncology
- Title of qualification awarded    Full Professor
- Dates (from-to)                    1993 – 2002
- Name and type of organisation    Pisa School of Medicine
- Principal subjects/occupational skills covered                    Clinical Oncology
- Title of qualification awarded    Professor

## **EDUCATION AND TRAINING**

- Date                                    1984
- Name and type of organisation providing education and training    Genova University
- Principal subjects/occupational skills covered                    Hematology
- Title of qualification awarded    Specialty
- Date                                    1980
- Name and type of organisation providing education and training    Milano University

- Principal subjects/occupational skills covered Clinical Immunology
- Title of qualification awarded Specialty
  - Dates 1977
- Name and type of organisation providing education and training Torino University
- Principal subjects/occupational skills covered Clinical Oncology
  - Title of qualification awarded Specialty
    - Date 1974
- Name and type of organisation providing education and training Torino University
  - Title of qualification awarded M.D.

MOTHER TONGUE **Italian**

OTHER LANGUAGES

**English**

- Reading skills EXCELLENT
- Writing skills EXCELLENT
- Verbal skills EXCELLENT

**ANNEXES**

- Research Grants**
- Committee and Chairmanship Awards**
- Scientific Publications**
- Scientific Affiliations**
- Editorial Board**
- Editorial Reviewer Board**

I conducted clinical research according to GCP.

## Research Grants

### Grants with the National Research Council (CNR)

- 1982-83 “Development of autoradiographic (PDP test) and cytofluorimetric techniques to study in vitro the growth fraction of human tumors”
- 1984-89 “Measurement of the growth fraction as a prognostic parameter and to design clinical protocols in breast and ovarian carcinoma”
- 1991-96 “Accelerated versus conventional chemotherapy in locally advanced breast cancer”
- 1998-99 “Evaluation of PET in breast carcinoma”
- 1999-2001 “Preoperative chemotherapy with the GET regimen in operable breast carcinoma”
- 2001-2003 “Design of anthracycline/taxane regimens according to the tumoral biological profile”

### Grants with the Italian Association for Cancer Research (AIRC)

- 1987-89 “Cytokinetic chemotherapy of breast cancer”
- 1989-92 “Biological modifiers: in vitro and in vivo effects on neoplastic cells”
- 1996-97 “Special Project Stem Cell in Oncology: selection and in vitro expansion of CD 34+ HSC derived from bone marrow and peripheral blood to support single or multiple cycles of high dose chemotherapy”
- 1998-2000 “Clinical studies to improve treatment outcomes in metastatic breast cancer patients”,
- 2003-2004 “Operable Breast Cancer : an in vivo model to integrate target directed therapies in the management of

operable breast cancer”

### **Grants with the Ministry of Research and Education**

- 2005-2007 “Primary systemic therapy for early breast cancer: clinical, biological and molecular outputs”

### **Grants with the Ministry of Health**

- 2006-2008 “Validation of new biomarkers: role in prognosis and therapy guidance” – Programma Integrato Oncologia
- 2009-2012 “Treatment optimization of HER2 positive breast cancer” – Progetto Finalizzato

### **Grants with other State Agencies**

- 2004-2007 “Gene therapy of solid tumors”- Interchange Program Italy-Hungaria- Italian Ministry for Foreign Affairs
- 2007-2009 “Short-HER: multicentric randomised phase III trial of adjuvant chemotherapy plus 3 vs 12 months of trastuzumab in breast cancer patients with HER2 positive disease”-AIFA-Italian Drug Agency

### **Grants with Regional Agencies**

- 1995-1996 “Pharmacokinetic evaluation of paclitaxel “ – Research Program of the Tuscany Government
- 2007-2009 “Identification and clinical validation of predictive and prognostic factors with special focus on molecularly targeted agents” – Research Program of Emilia Romagna Government – University
- 2013 present – “Impact of the Oncotype DX® Breast Cancer Assay on Resources Optimization and Treatment Decisions for Women with Estrogen Receptor- Positive, Node-Negative and Node-Positive Breast Carcinoma: a prospective Italian multicenter study” - Veneto Government
- 2014 present PRITHA project: “Organizational systems for patients with bone metastases in the Venetian Oncology Network”

### **Grants with University of Padua**

- 2013 present – MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance Aromatase Inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients with HR + metastatic breast cancer with disease control after first line chemotherapy
- 2013 present - PIK3CA pathway activation and tumor infiltrating lymphocytes (TIL) to predict outcome of HER+ early breast cancer (EBC) patients treated with trastuzumab based therapy in the prospective randomized phase III Short-Her trial.
- 2016 present – A-BRAVE Trial PHASE III RANDOMIZED TRIAL OF AN ANTI-PD-L1 ANTIBODY AS ADJUVANT OR POST-NEOADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS

### **Committee and Chairmanship**

- Founder and Chairman, Gruppo Oncologico Nord-Ovest 1983-1998
- Secretary, Italian Association of Medical Oncology (Liguria Section) 1984-1989
- Chairman, Italian Association of Medical Oncology (Liguria Section) 1989-1990
- Member, Executive Committee of the Italian Society of Cell Kinetics 1989-1992
- Member, Steering Committee International Cancer Cooperative Group (ICCG) 1992-present
- Member, National Executive Committee, Italian Association of Medical Oncology 1992-1993
- Chairman, Italian Association of Medical Oncology (Toscana Section) 1997-1999
- Member, National Executive Committee of the Italian Cancer Society 1997-1999
- Member, Board of Directors Bioethical Committee, Tuscany Regional Government 1993-1999
- Member, Meta-Analysis Group in Cancer 1994-present
- Member, National Cancer Committee of the Ministry of Health 1997-1999
- Faculty Member, European Society of Medical Oncology (ESMO) 1998-present
- Member, Clinical Discussion Forum European Society for Medical Oncology (Expert on Breast Cancer and Ovarian Cancer) 2002-present
- Founder and Chairman, Association Translation Research Oncology (ASTRO) 2002-present
- Referee, Italian Ministry of Health for the Continuous Medical Education (ECM) program 2002-present
- Vice Chairman, Cancer Committee, Emilia Romagna Regional Government 2006- present
- Member of the Anti Cancer Drug Committee of the Italian Drug Agency (AIFA) 2008- present
- Founder and Chairman, Association Research Education Oncology (AREO) 2009-present

- Chairman, Veneto Oncology Network, 2004-present
- Founder and President, Association Onlus PERIPLO 2017-present

## Awards

- 2007 Recipient of the Claude Jacquillat Award for Achievement in Clinical Oncology
- 2015 Stelle della Fenice in the world Award

## Scientific Publications

- Dr. Conte has published more than 400 papers in Peer Reviewed Journals. The majority of papers regard the biological characterization and clinical trials in ovarian and breast cancer
- **Total Impact Factor= as of November 28<sup>th</sup> 2017 = 2048,255;**
- as of November 28<sup>th</sup> 2017 **Total H Index = 59 (Scopus)**

## Scientific Affiliations

- Italian Association Medical Oncology (AIOM)
- Italian Cancer Society (SIC)
- European Society Medical Oncology (ESMO)
- American Society Clinical Oncology (ASCO)
- The Cell Kinetics Society
- International Gynecologic Cancer Society
- The New York Academy of Sciences
- Italian Society Basic & Applied Cell Kinetics (SICCAB)
- New England Cancer Society (Honorary Member)

## Editorial Board

- Clinical Breast Cancer
- Journal of Clinical Oncology
- Oncologie
- The Breast Journal
- Trends in Medicine
- The Oncologist

## Editorial Review Board

- Acta Hematologica
- Annals of Oncology
- British Journal of Cancer
- Cancer
- Clinical Drug Investigation
- Critical Review Oncology&Hematology
- Drugs
- European Journal of Cancer
- Expert Opinion in Pharmacotherapy
- Future Medicine
- Gynecologic Oncology
- Journal of Clinical Oncology
- Lancet
- Oncology
- Seminars in Oncology
- Tumori

I authorize the use of my personal data in compliance with Legislative Decree 196/2003.

Padua, November 29<sup>th</sup>, 2017

PierFranco Conte

